Skip to main content
. 2017 Feb 16;17:139. doi: 10.1186/s12885-017-3112-0

Table 1.

Verification of LOD with clinical samples

MPS Idylla™ KRAS Mutation Test
16S106 G12C (10% TTC: 31%VAF) G12C
16K11 G12C (5-10% TTC: 33% VAF) G12C
16O1048 G12V (10% TTC; 3% VAF) G12V
16EM117 G12D (10% TTC, 18%VAF) G12D

TTC tumor tissue content, VAF variant allele frequency